Stereotactic body radiotherapy (SBRT) for T2N0 (>3 cm) non-small cell lung cancer: Outcomes and failure patterns

Stephen J Shamp; Saad Sheikh; Tangel Chang; Nicholas Damico; Phillip Linden; Afshin Dowlati; Mitchell Machtay; Tithi Biswas

Stereotactic body radiotherapy (SBRT) for T2N0 (>3 cm) non-small cell lung cancer: Outcomes and failure patterns

J Radiosurg SBRT. 2021;7(4):271-277.

Authors

Stephen J Shamp¹, Saad Sheikh¹, Tangel Chang¹, Nicholas Damico¹, Phillip Linden¹, Afshin Dowlati¹, Mitchell Machtay¹, Tithi Biswas¹

Affiliation

¹ University Hospitals Cleveland Medical Center, 11000 Euclid Ave, Cleveland, OH 44106, USA.

PMID: 34631228
PMCID: PMC8492054

Abstract

Purpose/objectives: Outcomes of T2N0 lung cancer patients treated with stereotactic radiotherapy are not well known.

Methods and materials: We conducted a single institution retrospective review of patients with T2N0 NSCLC who were treated with SBRT. The local, regional, distant control rates were calculated from available clinical data. Survival outcomes were determined using the Kaplan Meier method.

Results: Fifty-six patients met our selection criteria. The two-year local control rate was 84.2%. The two and 5-year disease-free survival (DFS) and OS were 31.9% and 15.3% and 39.9% and 12.1%, respectively. Centroid BED₁₀ > 150Gy was associated with improved DFS, (p = 0.014), and OS on univariable analysis (p=0.0132).

Conclusions: SBRT provides good local control for T2N0 NSCLC, but systemic failure remains problematic.

Keywords: Radiosurgery; carcinoma; non-small-cell lung cancer; retrospective studies; treatment outcomes.